History of testicular cancer chemotherapy: Maximizing efficacy, minimizing toxicity

Seminars in Urologic Oncology

Volumn 19, Issue 3, 2001, Pages 170-179

  Sweeney, C ^a  

^a Indiana Cancer Pavilion   (United States)

Author keywords

Chemotherapy; Testicular cancer; Toxicity

Indexed keywords

ANTIBIOTIC AGENT; BLEOMYCIN; CALCIUM CHANNEL BLOCKING AGENT; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DEXAMETHASONE; ETOPOSIDE; GRANISETRON; NIFEDIPINE; ONDANSETRON; SEROTONIN ANTAGONIST; VINBLASTINE;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HISTORY; HUMAN; INFERTILITY; KIDNEY DISEASE; LUNG DISEASE; MALE; META ANALYSIS; METASTASIS; NAUSEA; NEUROPATHY; OTOTOXICITY; PRIORITY JOURNAL; REVIEW; SECOND CANCER; TESTIS CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; BONE MARROW; CARDIOVASCULAR DISEASES; CISPLATIN; ETOPOSIDE; GERMINOMA; HEARING DISORDERS; HUMANS; INFERTILITY, MALE; MALE; NAUSEA; NERVOUS SYSTEM DISEASES; TESTICULAR NEOPLASMS; VINBLASTINE; VOMITING;

EID: 0034873466     PISSN: 10810943     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Effects of combined drug therapy on metastatic cancer of the testis
2. Combination chemotherapy in germinal cell tumors
3. Diaminodichloroplatinum: A phase I study showing responses in testicular and other tumors
4. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer
5. High-dose versus low-dose vinblastine in cisplatin-vinblastinebleomycin combination chemotherapy of non-seminomatous testicular cancer: A randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group
6. VP16-213 as a single agent in advanced testicular tumors
7. Cis-dichlorodiammineplatinum(II): Combination chemotherapy and cross- resistance studies with tumors of mice
8. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide
9. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol
10. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group trial
11. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group
12. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors
13. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council
14. Are 3 cycles of bleomycin, etoposide and cisplatin (3BEP) or 4 cycles of etoposide and cisplatin (4EP) equivalent Regimens for patients (pts) good-risk metastatic non-seminomatous Germ cell tumors (NSGCT)? Preliminary results of a randomized trial
15. The effect of corticosteroid administration on bleomycin lung toxicity
16. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: A Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial
17. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: A multiinstitutional study
18. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study
19. Long term effect of cisdiamminedichloride platinum (CDDP) on renal function and structure in man
20. The long-term effect of cisplatin on renal function
21. Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma
22. Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer
23. Acute and long-term nephrotoxicity of cis-platinum in man
24. Platinum organ toxicity and possible prevention in patients with testicular cancer
25. Raynaud's phenomenon: A common toxicity after combination chemotherapy for testicular cancer
26. Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: Measurement of vasoconstrictor response to cold
27. Cisplatin-based combination chemotherapy for disseminated germ cell tumors: Long-term follow-up
28. Nifedipine and oncologic Raynaud phenomenon
29. Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis
30. Thromboembolic events during combination chemotherapy for germ cell-malignancy
31. Coronary artery disease after treatment with bleomycin and vinblastine
32. No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: An analysis of the Testicular Cancer Intergroup study
33. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer
34. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer
35. Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer
36. Evaluation of long-term toxicity after chemotherapy for testicular cancer
37. Ototoxicity in patients receiving cisplatin: Importance of dose and method of drug administration
38. Secondary leukemia associated with a conventional dose of etoposide: Review of serial germ cell tumor protocols
39. Therapy-related myelodysplasia and acute myeloid leukemia: Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series
40. The story of second cancers in patients cured of testicular cancer: Tarnishing success or burnishing irrelevance?
41. Second cancer risk following testicular cancer: A follow-up study of 1,909 patients
42. Risk of second malignant neoplasms among long-term survivors of testicular cancer
43. Increased incidence of sarcoma in patients treated for testicular seminoma
44. Fertility after chemotherapy for testicular cancer
45. Fertility status of patients with clinical stage I testis tumors on a surveillance protocol
46. Gonadal dysfunction
47. Gonadal function in men with testis cancer
48. Gonadal dysfunction in patients treated for metastatic germ-cell tumors
49. Testicular function in patients with testicular cancer treated with orchiectomy alone or orchiectomy plus cisplatin-based chemotherapy
50. The treatment of ejaculation disorders after retroperitoneal lymph node dissection
51. The fertility of patients with clinical stage I testis cancer managed by nerve sparing retroperitoneal lymph node dissection
52. Return of fertility after treatment for nonseminomatous testicular cancer: Changing concepts
53. Fertility after chemotherapy for testicular germ cell cancers
54. Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin
55. Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer